吉非替尼治疗晚期非小细胞肺癌的临床观察-肿瘤学专业论文.docxVIP

浙江大学硕士研究生论文期。20例患者的疗效均可评价，其中完全缓解0例(0／20)，部分缓解4例(们回，稳 浙江大学硕士研究生论文 期。20例患者的疗效均可评价，其中完全缓解0例(0／20)，部分缓解4例(们回，稳 定12例(12／20)，进展4例(4／2∞。全组客观缓解率为20％(坦0)，疾病控制率为∞ ％(16／20)。全组中位疾病进展时间为lO个月，总的生存时间为1～23个月(目前 中位生存时间尚未到达1，7例生存时间超过1年，1年生存率为35％，目前仍存活 16例(∞％)，其中10例(50％)仍处于疾病控制中。毒副反应主要为1、2级皮肤毒 性，其它副作用有腹泻、脱发、食欲下降、ALT升高、口角炎，均为轻度。其中 有1例患者因3～4级恶心呕吐而停止治疗。 结’论吉非替尼对传统化疗失败的晚期难治性非小细胞肺癌患者有较好的疗 效，不良反应轻，可以耐受，可以考虑作为晚期非小细胞肺癌的二线治疗方案。 关键词非小细胞肺癌靶向治疗表皮生长因子受体吉非替尼 浙江大学硕士研究生论文The 浙江大学硕士研究生论文 The clinical study of gefitinib in the treatment of advanced non-small cell lung cancer Medical oncology Medical college of Zhejiang University Master’S candidate Yu Wan Supervisor Hongming Pan Abstract Objective To investigate the efficacy，time to progression，survival time and toxicity of Gefitinib (Iressa)which is a target therapy agent inhibiting epidermal growth factor receptor(EGFR)-tyrosine“nase in the treatment of advanced non—small cell lung cancer(NSCLC)and to analyze the relative factors affecting the efficacy． Methods From March 2005 to March 2007，20 patients with advanced NSCLC who failed from previous first—line chemotherapy or couldn’t tolerate surgew，radiotherapy and chemotherapy wcrc treated by gefitinib in this trial．Gefitinib was administered orally at a dose of 250 mg daily until disease progressed or Scvcrc toxicity developed． 4 浙江大学硕士研究生论文 浙江大学硕士研究生论文 lksuits twenty patients were entered in this study．Patients(10 male,10 female)had a median age of 60 years(range 39-77 yem)with adenocarcinoma 14 cases,bronchoalveolar cell carcinoma 5 cases and squamous cell carcinoma lease．Overall response rate was 20％(4／20)and the disease control rat“r鼯p‘m∞and stable disease)was 80％ (16／20)．Median time to Wogre豁O)was 10 months．Overall survival time ranged from 1 month to 23 months．1 year survival rate Was 35％(7／20)．Of the 16 patients(80％弦ho are still alive when the last following--up time and the 10(55％) had stable disease．The main toxicity of gefitinib Was grade 1 or 2 skin toxidty．The other adverse reaction inc